ARS Pharma Readies Data In Response To FDA's Rejection For Its EpiPen Alternative For Severe Allergic Reactions
Portfolio Pulse from Vandana Singh
ARS Pharmaceuticals Inc (NASDAQ:SPRY) released topline results from a clinical study for its EpiPen alternative, neffy, showing positive outcomes compared to epinephrine intramuscular injections. The data will be submitted to the FDA in Q2 2024 as a response to a previous rejection. The study demonstrated that repeat doses of neffy, whether in the same or opposite nostrils, resulted in higher pharmacodynamic responses than injections, indicating its efficacy in reversing anaphylaxis symptoms. Following these results, William Blair upgraded ARS Pharmaceuticals to Outperform.
February 20, 2024 | 7:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ARS Pharmaceuticals Inc released positive study results for neffy, an EpiPen alternative, and plans to resubmit to the FDA in Q2 2024. William Blair upgraded the stock to Outperform.
The positive clinical study results for neffy indicate a significant step forward for ARS Pharmaceuticals in addressing the FDA's previous concerns, potentially leading to approval. The upgrade by William Blair reflects increased investor confidence in the company's prospects, likely contributing to the short-term stock price increase.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100